NAS8
NOTICE OF ACCEPTANCE OF SEC. 8 - E-MAILED
06/20/2026
Back to search
Official data from USPTO
PIONEERING CELL THERAPIES
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: United States
Quick snapshot
PIONEERING CELL THERAPIES
ST13
US500000087543744Class
42
Filing
87543744
Registration
5991584
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
29
Latest update
06/21/2026
Trademark type
Word
Nice classes
42
Filing date
07/26/2017
Registration date
02/18/2020
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
06/20/2026
Last transaction
06/21/2026
Responsible office
United States Patent and Trademark Office
Status code
701
Official register
Principal Register
Filing basis
Intent to use
First use anywhere
05/08/2018
First use in commerce
12/03/2019
Drawing code
4
Owner type
03
Owner location
Chicago, IL, US
Examiner
YI, CRYSTAL HAEIN
Current location
Historical data usage
Holders and representatives
Holders
CellTrans Inc.
Representatives
CellTrans Inc.
Technical classification
Nice Classes
Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 42
Product research and development; Scientific research for medical purposes in the field of cell therapies
Publications
History of USPTO decisions and trademark events.
29 publications found
8.OK
REGISTERED - SEC. 8 (6-YR) ACCEPTED
06/20/2026
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
06/20/2026
ES8R
TEAS SECTION 8 RECEIVED
03/09/2026
REM1
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
02/18/2025
R.PR
REGISTERED-PRINCIPAL REGISTER
02/18/2020
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
01/14/2020
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
01/13/2020
SUPC
STATEMENT OF USE PROCESSING COMPLETE
01/13/2020
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
01/09/2020
IUAF
USE AMENDMENT FILED
12/30/2019
EISU
TEAS STATEMENT OF USE RECEIVED
12/30/2019
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
07/30/2019
EX1G
SOU EXTENSION 1 GRANTED
07/26/2019
EXT1
SOU EXTENSION 1 FILED
07/26/2019
EEXT
SOU TEAS EXTENSION RECEIVED
07/26/2019
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
02/19/2019
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
12/25/2018
PUBO
PUBLISHED FOR OPPOSITION
12/25/2018
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
12/05/2018
ALIE
ASSIGNED TO LIE
11/12/2018
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
10/29/2018
RCSC
REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
04/27/2018
GNS3
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
10/26/2017
GNSL
LETTER OF SUSPENSION E-MAILED
10/26/2017
CNSL
SUSPENSION LETTER WRITTEN
10/26/2017
DOCK
ASSIGNED TO EXAMINER
10/26/2017
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
07/31/2017
NWAP
NEW APPLICATION ENTERED
07/29/2017
Continuous trademark protection
Get notified about every new filing that threatens PIONEERING CELL THERAPIES or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.